X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3837) 3837
Publication (669) 669
Newsletter (60) 60
Book Review (49) 49
Book Chapter (17) 17
Magazine Article (3) 3
Conference Proceeding (2) 2
Newspaper Article (2) 2
Data Set (1) 1
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2571) 2571
pharmacology & pharmacy (2062) 2062
ritonavir (1881) 1881
index medicus (1617) 1617
male (1487) 1487
hiv infections - drug therapy (1461) 1461
female (1302) 1302
adult (1192) 1192
infectious diseases (1011) 1011
middle aged (895) 895
hiv (815) 815
protease inhibitors (792) 792
ritonavir - pharmacology (758) 758
pharmacokinetics (721) 721
hiv protease inhibitors - pharmacology (692) 692
drug interactions (688) 688
lopinavir (680) 680
ritonavir - therapeutic use (679) 679
ritonavir - administration & dosage (658) 658
drug therapy, combination (632) 632
antiretroviral therapy (609) 609
microbiology (605) 605
hiv protease inhibitors - therapeutic use (574) 574
antiviral agents (556) 556
hiv infections - virology (505) 505
ritonavir - pharmacokinetics (504) 504
hiv-1 - drug effects (501) 501
anti-hiv agents - therapeutic use (498) 498
hiv protease inhibitors - pharmacokinetics (491) 491
virology (472) 472
animals (437) 437
therapy (423) 423
hiv protease inhibitors - administration & dosage (406) 406
anti-hiv agents - administration & dosage (388) 388
ritonavir - adverse effects (367) 367
treatment outcome (355) 355
anti-hiv agents - pharmacokinetics (344) 344
lopinavir/ritonavir (343) 343
drug therapy (342) 342
saquinavir (342) 342
viral load (334) 334
immunology (324) 324
hiv infection (323) 323
hiv protease inhibitors - adverse effects (322) 322
efficacy (314) 314
anti-hiv agents - pharmacology (309) 309
darunavir (305) 305
pharmacology/toxicology (297) 297
safety (294) 294
indinavir (291) 291
pharmacology (291) 291
in-vitro (289) 289
infection (281) 281
human-immunodeficiency-virus (279) 279
area under curve (277) 277
human immunodeficiency virus--hiv (269) 269
adolescent (265) 265
medicine & public health (265) 265
aged (258) 258
atazanavir sulfate (255) 255
drug combinations (253) 253
virus diseases (253) 253
anti-hiv agents - adverse effects (250) 250
protease inhibitor (250) 250
young adult (250) 250
research (249) 249
p-glycoprotein (248) 248
metabolism (246) 246
antiretroviral drugs (244) 244
hiv-1 - genetics (243) 243
analysis (237) 237
dosage and administration (234) 234
proteases (234) 234
highly active antiretroviral therapy (232) 232
drug-interactions (231) 231
hiv-1 (231) 231
cd4 lymphocyte count (229) 229
drugs (225) 225
efavirenz (224) 224
drug administration schedule (222) 222
nelfinavir (219) 219
atazanavir (218) 218
combination (215) 215
dose-response relationship, drug (215) 215
tenofovir (215) 215
hiv protease inhibitors - blood (210) 210
hiv-infected patients (208) 208
resistance (207) 207
antiretroviral therapy, highly active (205) 205
aids (204) 204
health aspects (202) 202
hiv-1-infected patients (200) 200
ritonavir - blood (196) 196
active antiretroviral therapy (188) 188
article (187) 187
genotype (182) 182
rna, viral - blood (181) 181
risk factors (180) 180
drug resistance, viral (179) 179
hiv infections - blood (178) 178
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3850) 3850
Spanish (37) 37
French (19) 19
Japanese (7) 7
Chinese (3) 3
German (3) 3
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 06/2018, Volume 62, Issue 6, p. e00029-18
Journal Article
PLoS ONE, ISSN 1932-6203, 2017, Volume 12, Issue 7, p. e0181357
Journal Article
AIDS, ISSN 0269-9370, 07/2012, Volume 26, Issue 11, pp. 1371 - 1385
Background: The effect of specific antiretrovirals on inflammation is unclear. Methods: A5224s was a substudy of A5202, which randomized HIV-infected... 
endothelial activation markers | abacavir | C-reactive protein | TNF alpha | inflammation markers | interleukin-6 | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | IMMUNOLOGY | HIV-INFECTED PATIENTS | TENOFOVIR-EMTRICITABINE | INDIVIDUAL ANTIRETROVIRAL DRUGS | VIROLOGY | CLINICAL-TRIALS | ACUTE MYOCARDIAL-INFARCTION | Anti-HIV Agents - pharmacology | Humans | Tumor Necrosis Factor-alpha - blood | Deoxycytidine - pharmacology | Male | Inflammation - blood | Tenofovir | Acquired Immunodeficiency Syndrome - immunology | C-Reactive Protein - metabolism | Interleukin-6 - blood | Atazanavir Sulfate | Adult | Female | Ritonavir - pharmacology | C-Reactive Protein - drug effects | Acquired Immunodeficiency Syndrome - blood | Emtricitabine | Dideoxynucleosides - pharmacology | HIV-1 - metabolism | Adenine - analogs & derivatives | Adenine - pharmacology | Inflammation - immunology | Biomarkers - blood | Acquired Immunodeficiency Syndrome - drug therapy | Organophosphonates - pharmacology | Tumor Necrosis Factor-alpha - drug effects | Benzoxazines - pharmacology | Lamivudine - pharmacology | Pyridines - pharmacology | Oligopeptides - pharmacology | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | nucleoside reverse transcriptase inhibitors | RNA | Ritonavir | tenofovir | Lamivudine | Inflammation | Efavirenz | CD4 antigen | Cell adhesion molecules | Interleukin 6 | Abacavir | Age | Tumor necrosis factor- alpha
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 2004, Volume 4, Issue 10, pp. 1079 - 1095
There are currently (July, 2002) six protease inhibitors approved for the treatment of HIV infection, each of which can be classified as peptidomimetic in... 
CHEMISTRY, MEDICINAL | REVERSE-TRANSCRIPTASE INHIBITORS | ORALLY BIOAVAILABLE INHIBITOR | BIOLOGICAL EVALUATION | ANTIVIRAL ACTIVITY | SOCIETY-USA PANEL | ANTIRETROVIRAL THERAPY | INFECTED PATIENTS | HUMAN-IMMUNODEFICIENCY-VIRUS | TYPE-1 PROTEASE | STRUCTURE-BASED DESIGN | Anti-HIV Agents - pharmacology | Pyridines - chemistry | Humans | Saquinavir - therapeutic use | Urethane - chemistry | Pyrimidinones - chemistry | Oligopeptides - therapeutic use | HIV Protease Inhibitors - pharmacology | Saquinavir - pharmacology | Urethane - therapeutic use | Atazanavir Sulfate | Phenylbutyrates - pharmacology | Ritonavir - therapeutic use | Oligopeptides - chemistry | Saquinavir - chemistry | Lopinavir | Pyrimidinones - therapeutic use | Models, Molecular | Sulfonamides - pharmacology | HIV Protease Inhibitors - therapeutic use | Nelfinavir - pharmacology | Anti-HIV Agents - chemistry | Carbamates | Urethane - pharmacology | Oligopeptides - pharmacology | Organophosphates - therapeutic use | Indinavir - pharmacology | Urethane - analogs & derivatives | HIV - drug effects | Molecular Mimicry | Phenylbutyrates - chemistry | Anti-HIV Agents - therapeutic use | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Molecular Structure | Pyridines - therapeutic use | Nelfinavir - therapeutic use | Peptides - chemistry | Sulfonamides - chemistry | Dipeptides - pharmacology | HIV Protease Inhibitors - chemistry | Clinical Trials as Topic | Dipeptides - chemistry | Ritonavir - chemistry | Peptides - pharmacology | Organophosphates - pharmacology | Sulfonamides - therapeutic use | HIV Infections - drug therapy | Organophosphates - chemistry | Pyridines - pharmacology | Peptides - therapeutic use | Indinavir - therapeutic use
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 10, pp. 769 - 779
Journal Article
Drugs, ISSN 0012-6667, 6/2015, Volume 75, Issue 9, pp. 1027 - 1038
A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | PEGINTERFERON/RIBAVIRIN | PHASE 3B TRIAL | ABT-450/R-OMBITASVIR | TREATMENT-NAIVE ADULTS | FREE THERAPY | PHARMACOLOGY & PHARMACY | TOXICOLOGY | TREATMENT-EXPERIENCED ADULTS | 12-WEEK TREATMENT | HEPATITIS-C | RIBAVIRIN RBV | ABT-450/R/OMBITASVIR | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Drug Resistance, Viral | Anilides - pharmacokinetics | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Macrocyclic Compounds - pharmacology | Uracil - pharmacology | Ritonavir - adverse effects | Ritonavir - therapeutic use | Ritonavir - pharmacology | Drug Therapy, Combination | Drug Resistance | Carbamates - pharmacology | Liver Cirrhosis - drug therapy | Antiviral Agents - therapeutic use | Liver Cirrhosis - complications | Macrocyclic Compounds - pharmacokinetics | Uracil - therapeutic use | Genotype | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Macrocyclic Compounds - therapeutic use | Ritonavir - pharmacokinetics | Uracil - adverse effects | Sulfonamides - therapeutic use | Anilides - pharmacology | HIV Infections - complications | Sulfonamides - adverse effects | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Uracil - pharmacokinetics | Uracil - analogs & derivatives | Hepatitis C | Care and treatment
Journal Article
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 06/2004, Volume 48, Issue 6, pp. 2091 - 2096
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 4/2012, Volume 29, Issue 4, pp. 972 - 982
To predict and determine whether the protease inhibitors (PIs) nelfinavir, amprenavir, atazanavir, ritonavir, and saquinavir could serve as metabolic... 
Biochemistry, general | Biomedical Engineering | drug-drug interactions | Biomedicine | Pharmacy | carboxylesterase 1 | protease inhibitors | Medical Law | carboxylesterase 1 inhibitors | in vitro inhibition | Pharmacology/Toxicology | computational modeling | Carboxylesterase 1 | Drug-drug interactions | Carboxylesterase 1 inhibitors | Computational modeling | Protease inhibitors | In vitro inhibition | COCAINE | ANTIRETROVIRAL THERAPY | CHEMISTRY, MULTIDISCIPLINARY | NELFINAVIR | HEROIN | HIV-INFECTION | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PHARMACOKINETIC INTERACTIONS | SIMVASTATIN | Nelfinavir - chemistry | Carboxylic Ester Hydrolases - chemistry | Pyridines - chemistry | Humans | Carbamates - chemistry | Saquinavir - pharmacology | Protease Inhibitors - pharmacology | Drug Interactions | Antiviral Agents - chemistry | Atazanavir Sulfate | Ritonavir - pharmacology | Oligopeptides - chemistry | Quantitative Structure-Activity Relationship | Carbamates - pharmacology | Antiviral Agents - pharmacology | Carboxylic Ester Hydrolases - antagonists & inhibitors | Saquinavir - chemistry | Sulfonamides - chemistry | Models, Molecular | Protease Inhibitors - chemistry | Sulfonamides - pharmacology | Ritonavir - chemistry | Nelfinavir - pharmacology | Pyridines - pharmacology | Kinetics | Oligopeptides - pharmacology | Carboxylic Ester Hydrolases - metabolism | Drugs | Antiviral agents | Pharmacogenetics | Computer-generated environments | Computer simulation | Proteases | Analysis | Drug interactions | Universities and colleges | Anti-HIV agents | Drug therapy | Models
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, p. e113957
Background: Aspartic peptidase inhibitors have shown antimicrobial action against distinct microorganisms. Due to an increase in the occurrence of Chagas'... 
IN-VITRO | TRYPOMASTIGOTE FORMS | MULTIDISCIPLINARY SCIENCES | DRUGS | CHAGAS-DISEASE | RHODNIUS-PROLIXUS-MIDGUT | INFECTION | LEISHMANIA-AMAZONENSIS | DIFFERENTIATION | PROTEASE INHIBITORS | CELL-DEATH | Anti-HIV Agents - pharmacology | Microscopy, Electron, Transmission | Lopinavir - pharmacology | Indinavir - pharmacology | Sulfonamides - pharmacology | Aspartic Acid Proteases - metabolism | Nelfinavir - pharmacology | Saquinavir - pharmacology | Host-Parasite Interactions - drug effects | Protease Inhibitors - pharmacology | Animals | Trypanosoma cruzi - growth & development | Trypanocidal Agents - pharmacology | Insect Vectors - parasitology | Trypanosoma cruzi - drug effects | Ritonavir - pharmacology | Aspartic Acid Proteases - antagonists & inhibitors | Trypanosoma cruzi - ultrastructure | Carbamates - pharmacology | Infection | Antiviral agents | Calpain | HIV (Viruses) | Health aspects | Flow cytometry | Ritonavir | Immunoblotting | Parasites | Phylogeny | Trypomastigotes | Alterations | Microorganisms | Acquired immune deficiency syndrome--AIDS | Etiology | Human immunodeficiency virus--HIV | Nelfinavir | Cruzipain | Cathepsin D | Pretreatment | Cell body | Vector-borne diseases | Protozoa | Peptidase | Lopinavir | Substrate inhibition | Decoding | Peptidases | Detachment | Transmission electron microscopy | Disease transmission | Inhibitors | Epimastigotes | Chagas' disease | Cell size | Flagella | Viability | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article